No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Vieworks Co., Ltd. is dedicated to the development, manufacturing, and sale of comprehensive imaging systems and solutions. The company provides X-ray detectors alongside image processing technologies utilized across numerous fields, including general and veterinary radiography systems, dental and surgical C-arm systems, radiography and fluoroscopy setups, and industrial inspection instruments. Beyond its X-ray offerings, Vieworks also produces industrial-grade cameras and specialized bio-imaging systems, which encompass in vivo imaging solutions under the VISQUE brand. Founded in 1999, the organization was formerly known as Raysis Co., Ltd. before officially changing its name to Vieworks Co., Ltd. in November 2006. The company maintains its headquarters in Anyang-si, South Korea.
www.vieworks.comNo one on the platform currently holds 100120.KQ.
No tracked institution reports a position in 100120.KQ as of their last filing.
No one on the platform has traded 100120.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.1% | 10.6% | 17.2% | — | — | — |
| Rev. Growth % | 7.4% | 8.4% | ||||
| Profit Margin % | 9.2% | 10.8% | 14.1% | |||
| Free Cash Flow Margin % | 3.4% | 1.7% | 4.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $252.8B | +7.4% | $5027.00 | $4264.60–$5789.40 | — | 2 |
| 2027 | $264.2B | +4.5% | $5287.00 | $4338.00–$6607.60 | — | 3 |
| 2028 | $275.2B | +4.2% | $6028.00 | $5935.27–$6138.41 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $2670.00 |
| -7.45% |
| $48.4B |
| — |
| 036220.KQOsang Healthcare Co.,Ltd | $6840.00 | -2.29% | $94.1B | — |
| 234080.KSJW Lifescience Corporation | $10980.00 | +0.18% | $170.0B | — |
Source: Financial Modeling Prep · peers by sector/industry